Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Review, H1 2016 - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Review, H1 2016" report to their offering.

This report provides comprehensive information on the therapeutic development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency)) and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Key Topics Covered:

  1. Introduction
  2. Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Overview
  3. Therapeutics Development
  4. Pipeline Products for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Overview
  5. Pipeline Products for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Comparative Analysis
  6. Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Therapeutics under Development by Companies
  7. Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Therapeutics under Investigation by Universities/Institutes
  8. Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Products under Development by Companies
  13. Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Products under Investigation by Universities/Institutes
  14. Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Companies Involved in Therapeutics Development
  • Adverum Biotechnologies, Inc.
  • Arrowhead Pharmaceuticals, Inc.
  • BioCryst Pharmaceuticals, Inc.
  • Cevec Pharmaceuticals GmbH
  • CSL Limited
  • Global Blood Therapeutics, Inc.
  • iBio, Inc.
  • Ionis Pharmaceuticals, Inc.
  • Pharming Group N.V.
  • ProMetic Life Sciences Inc.
  • Ra Pharmaceuticals, Inc.
  • Shire Plc

For more information visit http://www.researchandmarkets.com/research/dfq2bh/hereditary

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Immune Disorders Drugs, Enzymes

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Immune Disorders Drugs, Enzymes